Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses

H. C. Casbeer, Heather K Knych

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Tolazoline is an α2-adrenergic receptor antagonist, used in veterinary medicine to antagonize the central nervous system depressant and cardiovascular effects of α2 receptor agonists. The pharmacokinetics and pharmacodynamic effects of tolazoline when administered subsequent to detomidine in the horse were recently reported, although the reversal of the sedative and cardiovascular effects following detomidine may not be complete. The current study therefore investigated the pharmacokinetics and pharmacodynamic effects of tolazoline when administered as a sole agent. Nine healthy adult horses were administered tolazoline (4mg/kgIV) and blood samples were collected at time 0 (prior to drug administration) and at various times up to 72h post drug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry and resulting data analyzed using compartmental analysis. Systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.820 ± 0.182. L/h/kg, 1.68 ± 0.379. L/kg and 2.69 ± 0.212. h, respectively. Tolazoline administration had no effect on chin to ground distance, but the heart rate decreased (relative to baseline) and the percentage of atrial-ventricular block increased in all horses within 2. min of administration. Packed cell volume and glucose concentrations were also increased throughout the sampling period. While not commonly used as a sole agent, caution is indicated whenever tolazoline is administered since the effects may be unpredictable.

Original languageEnglish (US)
Pages (from-to)504-509
Number of pages6
JournalVeterinary Journal
Volume196
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Tolazoline
pharmacology
intravenous injection
Intravenous Administration
pharmacokinetics
Horses
detomidine
Pharmacokinetics
horses
drugs
sedatives
adrenergic receptors
sampling
liquid chromatography
veterinary medicine
agonists
half life
hematocrit
central nervous system
heart rate

Keywords

  • Horse
  • Pharmacodynamics
  • Pharmacokinetics
  • Tolazoline

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses. / Casbeer, H. C.; Knych, Heather K.

In: Veterinary Journal, Vol. 196, No. 3, 06.2013, p. 504-509.

Research output: Contribution to journalArticle

@article{d5c8d040e7b84db6882b5f7719916864,
title = "Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses",
abstract = "Tolazoline is an α2-adrenergic receptor antagonist, used in veterinary medicine to antagonize the central nervous system depressant and cardiovascular effects of α2 receptor agonists. The pharmacokinetics and pharmacodynamic effects of tolazoline when administered subsequent to detomidine in the horse were recently reported, although the reversal of the sedative and cardiovascular effects following detomidine may not be complete. The current study therefore investigated the pharmacokinetics and pharmacodynamic effects of tolazoline when administered as a sole agent. Nine healthy adult horses were administered tolazoline (4mg/kgIV) and blood samples were collected at time 0 (prior to drug administration) and at various times up to 72h post drug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry and resulting data analyzed using compartmental analysis. Systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.820 ± 0.182. L/h/kg, 1.68 ± 0.379. L/kg and 2.69 ± 0.212. h, respectively. Tolazoline administration had no effect on chin to ground distance, but the heart rate decreased (relative to baseline) and the percentage of atrial-ventricular block increased in all horses within 2. min of administration. Packed cell volume and glucose concentrations were also increased throughout the sampling period. While not commonly used as a sole agent, caution is indicated whenever tolazoline is administered since the effects may be unpredictable.",
keywords = "Horse, Pharmacodynamics, Pharmacokinetics, Tolazoline",
author = "Casbeer, {H. C.} and Knych, {Heather K}",
year = "2013",
month = "6",
doi = "10.1016/j.tvjl.2012.12.006",
language = "English (US)",
volume = "196",
pages = "504--509",
journal = "Veterinary Journal",
issn = "1090-0233",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses

AU - Casbeer, H. C.

AU - Knych, Heather K

PY - 2013/6

Y1 - 2013/6

N2 - Tolazoline is an α2-adrenergic receptor antagonist, used in veterinary medicine to antagonize the central nervous system depressant and cardiovascular effects of α2 receptor agonists. The pharmacokinetics and pharmacodynamic effects of tolazoline when administered subsequent to detomidine in the horse were recently reported, although the reversal of the sedative and cardiovascular effects following detomidine may not be complete. The current study therefore investigated the pharmacokinetics and pharmacodynamic effects of tolazoline when administered as a sole agent. Nine healthy adult horses were administered tolazoline (4mg/kgIV) and blood samples were collected at time 0 (prior to drug administration) and at various times up to 72h post drug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry and resulting data analyzed using compartmental analysis. Systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.820 ± 0.182. L/h/kg, 1.68 ± 0.379. L/kg and 2.69 ± 0.212. h, respectively. Tolazoline administration had no effect on chin to ground distance, but the heart rate decreased (relative to baseline) and the percentage of atrial-ventricular block increased in all horses within 2. min of administration. Packed cell volume and glucose concentrations were also increased throughout the sampling period. While not commonly used as a sole agent, caution is indicated whenever tolazoline is administered since the effects may be unpredictable.

AB - Tolazoline is an α2-adrenergic receptor antagonist, used in veterinary medicine to antagonize the central nervous system depressant and cardiovascular effects of α2 receptor agonists. The pharmacokinetics and pharmacodynamic effects of tolazoline when administered subsequent to detomidine in the horse were recently reported, although the reversal of the sedative and cardiovascular effects following detomidine may not be complete. The current study therefore investigated the pharmacokinetics and pharmacodynamic effects of tolazoline when administered as a sole agent. Nine healthy adult horses were administered tolazoline (4mg/kgIV) and blood samples were collected at time 0 (prior to drug administration) and at various times up to 72h post drug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry and resulting data analyzed using compartmental analysis. Systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.820 ± 0.182. L/h/kg, 1.68 ± 0.379. L/kg and 2.69 ± 0.212. h, respectively. Tolazoline administration had no effect on chin to ground distance, but the heart rate decreased (relative to baseline) and the percentage of atrial-ventricular block increased in all horses within 2. min of administration. Packed cell volume and glucose concentrations were also increased throughout the sampling period. While not commonly used as a sole agent, caution is indicated whenever tolazoline is administered since the effects may be unpredictable.

KW - Horse

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Tolazoline

UR - http://www.scopus.com/inward/record.url?scp=84879413243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879413243&partnerID=8YFLogxK

U2 - 10.1016/j.tvjl.2012.12.006

DO - 10.1016/j.tvjl.2012.12.006

M3 - Article

C2 - 23321455

AN - SCOPUS:84879413243

VL - 196

SP - 504

EP - 509

JO - Veterinary Journal

JF - Veterinary Journal

SN - 1090-0233

IS - 3

ER -